Products

CAT # Product Name Description
CPD109545 Asundexian,BI1265162 Asundexian (BAY 2433334) is an oral active coagulation factor FXIa inhibitor.
CPD115140 (3-fluoro-4-methoxypyridin-2-yl)methanamine
CPD110174 BMS-986278 BMS-986278 is an effective and orally active blood phospholipid receptor 1 (LPA1) antagonist.
CPD112674 (1S,3S)-3-hydroxycyclohexane-1-carboxylic acid
CPD114162 (1R,2R)-2-methoxycyclobutan-1-amine hydrochloride
CPD111050 Ifebemtinib,BI 853520 Ifebemtinib (BI 853520) is a potent inhibitor of focal adhesion kinase (FAK) with oral activity.
CPDM400065 GSLPSDPDUANRCA-UHFFFAOYSA-N
CPD109439 1H-Imidazole-1-ethanamine, N-(2,2-dimethylpropy...
CPDM400064 ((3aR,5S,6R,6aR)-6-(dibenzylamino)-2,2-dimethyl...
CPD100715 (R)-1-(3-nitro-5-(trifluoromethyl)phenyl)ethan-...
CPD107407 Carbamic acid, N-[4-(2-amino[1,2,4]triazolo[1,5...
CPD107408 (R)-2-(4-fluorophenyl)propanoic acid
CPD1224 GSK-2018682 GSK2018682 is an agonist for S1P1 and S1P5 receptors.
CPD0555 tert-butyl 1-(2,5-difluorophenyl)-1-oxopent-4-y...
CPD0102 4-(2-CARBOXY-ETHYL)-2-METHYL-1H-PYRROLE-3-CARBO...
CPD0566 8-acetyl-6-(benzyloxy)-2H-benzo[b][1,4]oxazin-3...
CPD0166 6-methoxyindoline-5-carbaldehyde
CPD1018 BAR 501 impurity
CPD100287 Fasiglifam,TAK-875 Fasiglifam (TAK-875) is an effective, oral, and selective GPR40 agonist.
CPD1023 8-Bromo-5-(methylthio)[1,2,4]triazolo[4,3-c]pyr...
CPD0928 4-Methoxy-2(3H)-benzothiazolone
CPD100239 Dapagliflozin Propanediol Monohydrate Dapagliflozin ((2S) -1,2-propanediol, hydrate) is the S isomer of Dapagliflozin 1,2-propanediol, hydrate, used in the study of diabetes (DM), is a competitive inhibitor of glucose cotransporter 2 (SGLT2), which can lead to glucose excretion in urine.
CPD1127 Bicyclo[3.2.0]hept-3-ene-6-acetic acid, 6- (ami...
CPD1033 di-tert-butyl 4-bromo-2-nitrophenylcarbamate


Contact Us

Inquiry

Latest News

  • Top 7 Trends In Pharmaceutical Research In 2018

    Top 7 Trends In Pharmaceutical Research I...

      Being under ever-increasing pressure to compete in a challenging economic and technological environment, pharmaceutical and biotech companies must continually innovate in their R&D programmes to stay ahead ...

  • ARS-1620: A promising new inhibitor for KRAS-mutant cancers

    ARS-1620: A promising new inhibitor for K...

    According to a study published in Cell, researchers have developed a specific inhibitor for KRASG12C called ARS-1602 that induced tumor regression in mice. “This study provides in vivo evidence that mutant KRAS can be...

  • AstraZeneca receives regulatory boost for oncology drugs

    AstraZeneca receives regulatory boost for...

    AstraZeneca received a double boost for its oncology portfolio on Tuesday, after US and European regulators accepted regulatory submissions for its drugs, the first step towards winning approval for these medicines. ...

WhatsApp Online Chat !